Novo says its next-gen obesity drug tops Lilly rival in late-stage study
Sept 21 (Reuters) – Novo Nordisk said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli Lilly’s drug.
Read more Indian River County Commission District 2 candidates answer questions
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
Copyright Reuters or USA Today Network via Reuters Connect
This story was originally published September 21, 2026 at 6:46 AM.
Post Comment